Investigating nanobodies to target multidrug resistant bacterial pathogens
研究针对多重耐药细菌病原体的纳米抗体
基本信息
- 批准号:10225294
- 负责人:
- 金额:$ 68.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AmericanAnti-Bacterial AgentsAnti-Infective AgentsAntibioticsAntibodiesAntibody TherapyBackBacteriaBacterial Antibiotic ResistanceBacterial InfectionsBindingCessation of lifeChemistryComplementarity Determining RegionsConserved SequenceDevelopmentFailureFutureImmuneInfectionInvadedLeadLengthMedicalMethodsModalityMolecularMolecular TargetMulti-Drug ResistanceMultiple Bacterial Drug ResistanceNaturePeptide AntibioticsPeptidesPharmacologyPopulationPropertyResearchRiskSlideStructureSurfaceSurface AntigensTestingTherapeuticTherapeutic UsesTherapeutic antibodiesToxinVertebral columnWorkantimicrobialantimicrobial drugantimicrobial peptidebasecell envelopefight againstimmune functionin vivoinsightlead optimizationmicrobiomemulti-drug resistant pathogennanobodiesnovel therapeuticspathogenpathogenic bacteriapreventquantumscreeningsmall moleculetooltranslational impact
项目摘要
Project Summary.
While rates of antibiotic resistance bacterial infections continue to rise, our development of new antimicrobials
has stagnated. The failure of traditional small molecule leads to restock are arsenal demands the development
of alternative approaches to prevent our slide back to the pre-antibiotic medical era. Antimicrobial peptides are
highly effective against multidrug resistant pathogens but have poor pharmacological properties hindering their
in vivo use. Antibodies have excellent pharmacological properties but generally lack direct antimicrobial action,
which limits their therapeutic use in treating infection, especially in immune compromised populations most at
risk for multidrug resistant infection. The objective of this proposal is to develop a new therapeutic paradigm
that joins the direct action of antimicrobial peptide antibiotics with the benefits of antibody structure in a single
antimicrobial agent. To develop this new modality we are leveraging the unique qualities of variable heavy
chain domain of Camelid heavy chain antibodies, known as a VHH or nanobody. Supported by a high-
throughput approaches for lead antimicrobial nanobody identification we have developed, this new paradigm
takes advantage of the benefit of direct antimicrobial peptide activity while providing a modular way to multiplex
peptide action in a pharmacologically beneficial nanobody backbone structure. Our approach has the ability to
identify both broad spectrum and target antimicrobials to selectively eliminate invading pathogens.
Furthermore, our approach has the future potential to utilize immune functions for enhanced pathogen
clearance. This proposal offers a quantum leap forward in anti-infective research. Completion of the planned
work is expected to have a positive translational impact by introducing a new direction in immune based anti-
infective therapy and new high-throughput tools for lead antimicrobial nanobody discovery, both of which will
support the fight against antibiotic resistant bacteria.
!
!
项目摘要。
虽然抗生素耐药性细菌感染率持续上升,但我们开发的新抗菌药物
已经停滞了。传统小分子的失败导致补货是军火库需求的发展
防止我们回到抗生素前医疗时代的替代方法。抗菌肽是
对多重耐药病原体非常有效,但药理学特性较差,阻碍了其发挥作用
体内使用。抗体具有优异的药理学特性,但通常缺乏直接的抗菌作用,
这限制了它们在治疗感染方面的治疗用途,尤其是在免疫受损人群中
多重耐药感染的风险。该提案的目的是开发一种新的治疗范式
将抗菌肽抗生素的直接作用与抗体结构的优点结合在一个单一的
抗菌剂。为了开发这种新模式,我们正在利用可变重量的独特品质
骆驼重链抗体的链结构域,称为 VHH 或纳米抗体。由高支持
我们开发了用于先导抗菌纳米抗体鉴定的通量方法,这种新范例
利用直接抗菌肽活性的优势,同时提供模块化的多重检测方法
肽在药理学上有益的纳米抗体骨架结构中的作用。我们的方法能够
识别广谱和靶向抗菌药物,以选择性地消除入侵的病原体。
此外,我们的方法未来有潜力利用免疫功能增强病原体
清除。该提案为抗感染研究带来了巨大的飞跃。完成计划
通过引入基于免疫的抗病毒新方向,预计工作将产生积极的转化影响。
感染疗法和用于领先抗菌纳米抗体发现的新高通量工具,这两者都将
支持对抗抗生素耐药细菌。
!
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bryan William Davies其他文献
Bryan William Davies的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bryan William Davies', 18)}}的其他基金
Investigation of capsule interactions that promote antimicrobial peptide activity
促进抗菌肽活性的胶囊相互作用的研究
- 批准号:
10193371 - 财政年份:2021
- 资助金额:
$ 68.66万 - 项目类别:
Investigation of capsule interactions that promote antimicrobial peptide activity
促进抗菌肽活性的胶囊相互作用的研究
- 批准号:
10378034 - 财政年份:2021
- 资助金额:
$ 68.66万 - 项目类别:
Investigating nanobodies to target multidrug resistant bacterial pathogens
研究针对多重耐药细菌病原体的纳米抗体
- 批准号:
10661648 - 财政年份:2020
- 资助金额:
$ 68.66万 - 项目类别:
Investigating nanobodies to target multidrug resistant bacterial pathogens
研究针对多重耐药细菌病原体的纳米抗体
- 批准号:
10455104 - 财政年份:2020
- 资助金额:
$ 68.66万 - 项目类别:
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study
用于抗菌药物发现和研究的高通量分子平台
- 批准号:
9923526 - 财政年份:2016
- 资助金额:
$ 68.66万 - 项目类别:
A High-Throughput Molecular Platform for Antimicrobial Discovery and Study
用于抗菌药物发现和研究的高通量分子平台
- 批准号:
9155253 - 财政年份:2016
- 资助金额:
$ 68.66万 - 项目类别:
相似海外基金
New technologies for targeted delivery of anti-bacterial agents
抗菌药物靶向递送新技术
- 批准号:
1654774 - 财政年份:2015
- 资助金额:
$ 68.66万 - 项目类别:
Studentship
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
- 批准号:
8416313 - 财政年份:2012
- 资助金额:
$ 68.66万 - 项目类别:
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
- 批准号:
8298885 - 财政年份:2012
- 资助金额:
$ 68.66万 - 项目类别: